NCT03872206: A trial that was reported late by Harpoon Therapeutics
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03872206 |
|---|---|
| Title | A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 16, 2019 |
| Completion date | Jan. 4, 2023 |
| Required reporting date | Jan. 4, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 12, 2024 |
| Days late | 155 |